Jim Simons Aprea Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	SELL	$0.32 - $15.2 $33,069 - $1.57 Million	-103,341 Reduced 36.58%	179,200 $59,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $20,741 - $397,296	-29,213 Reduced 9.37%	282,541 $184,000
Q2 2022 Aug 12, 2022	BUY	$0.62 - $1.94 $8,589 - $26,876	13,854 Added 4.65%	311,754 $234,000
Q1 2022 May 13, 2022	BUY	$1.59 - $3.16 $25,403 - $50,487	15,977 Added 5.67%	297,900 $554,000
Q4 2021 Feb 11, 2022	BUY	$2.87 - $5.58 $809,119 - $1.57 Million	281,923 New	281,923 $809,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,885
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.